Search Results - (Author, Cooperation:H. Jasper)
-
1Staff View
Publication Date: 2015-12-04Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Animals ; Calcium/*metabolism ; Cell Proliferation/drug effects ; Cytosol/chemistry ; Diet ; Drosophila melanogaster/*cytology/drug effects/metabolism ; Glutamic Acid/pharmacology ; Intestines/cytology ; Receptors, Metabotropic Glutamate/metabolism ; *Signal Transduction ; Stem Cells/*cytology/metabolismPublished by: -
2Jasper H. M. van der Velde; Jens Oelerich; Jingyi Huang; Jochem H. Smit; Atieh Aminian Jazi; Silvia Galiani; Kirill Kolmakov; Giorgos Gouridis; Christian Eggeling; Andreas Herrmann; Gerard Roelfes; Thorben Cordes
Nature Publishing Group (NPG)
Published 2018Staff ViewPublication Date: 2018-07-25Publisher: Nature Publishing Group (NPG)Electronic ISSN: 2041-1723Topics: BiologyChemistry and PharmacologyNatural Sciences in GeneralPhysicsPublished by: -
3Staff View
Publication Date: 2018-10-05Publisher: Genetics Society of America (GSA)Print ISSN: 0016-6731Topics: BiologyPublished by: -
4ANDREWS, H. L. ; JASPER, H. H.
Provincetown, Mass., etc. : Periodicals Archive Online (PAO)
Published 1936Staff ViewISSN: 0022-1309Topics: PsychologyURL: -
5JASPER, H. H. ; ANDREWS, H. L.
Provincetown, Mass., etc. : Periodicals Archive Online (PAO)
Published 1936Staff ViewISSN: 0022-1309Topics: PsychologyURL: -
6JASPER, H. H. ; ANDREWS, H. L.
Provincetown, Mass., etc. : Periodicals Archive Online (PAO)
Published 1936Staff ViewISSN: 0022-1309Topics: PsychologyURL: -
7Staff View
ISSN: 0016-6480Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: BiologyMedicineType of Medium: Electronic ResourceURL: -
8Staff View
ISSN: 1749-6632Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: Natural Sciences in GeneralType of Medium: Electronic ResourceURL: -
9ANDREWS, H. L. ; JASPER, H. H.
Provincetown, Mass., etc. : Periodicals Archive Online (PAO)
Published 1936Staff ViewISSN: 0022-1309Topics: PsychologyURL: -
10Staff View
ISSN: 0002-9556Topics: PsychologyNotes: ARTICLES AND NOTESURL: -
11Staff View
ISSN: 0002-9556Topics: PsychologyNotes: ARTICLES AND NOTESURL: -
12Staff View
ISSN: 0002-9556Topics: PsychologyNotes: BOOK REVIEWSURL: -
13Staff View
ISSN: 0002-9556Topics: PsychologyNotes: BOOK REVIEWSURL: -
14Staff View
ISSN: 0307-1847Topics: Political ScienceURL: -
15Staff View
ISSN: 0307-1847Topics: Political ScienceURL: -
16Staff View
ISSN: 0307-1847Topics: Political ScienceURL: -
17Staff View
ISSN: 0307-1847Topics: Political ScienceURL: -
18Staff View
ISSN: 0307-1847Topics: Political ScienceURL: -
19Ferraris, J. R. ; Pasqualini, T. ; Legal, S. ; Sorroche, P. ; Galich, A. M. ; Pennisi, P. ; Domene, H. ; Jasper, H.
Springer
Published 2000Staff ViewISSN: 1432-198XKeywords: Key words Growth ; Growth factors ; Dislipoproteinemia ; Bone mineral density ; Serum leptin ; Renal transplantation ; DeflazacortSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Kidney function, growth velocity, weight/ height ratio, body composition, lipid profile, and bone mass were studied in a randomized, multicenter trial of deflazacort versus methylprednisone in 27 prepubertal patients with kidney transplantation. Methylprednisone (0.20±0.03) was replaced by deflazacort (13 patients, 0.30±0.03 mg/kg per day). After 12 months, creatinine clearance decreased significantly only during methylprednisone therapy. Growth velocity increased only in patients treated with deflazacort from 3.3±0.6 to 5.6±0.5 cm/year. Serum levels of several components of the insulin-like growth factor axis did not change. Weight/height ratio was increased in methylprednisone-treated patients (P〈0.05) and decreased in deflazacort-treated patients (P〈0.005). Lean body mass increased in both groups (P〈0.005). Fat body mass and serum leptin increased only in methylprednisone-treated patients (P〈0.025). Total cholesterol and low-density lipoprotein-cholesterol increased in methylprednisone-treated patients by 9.9% (P〈0.05) and 12.5% (P〈0.025). High-density lipoprotein-cholesterol increased by 21% (P〈0.005) and apolipoprotein B decreased by 11% (P〈0.005) in deflazacort-treated patients. Total skeleton and lumbar spine bone mineral density decreased in both groups, but at 1 year methylprednisone-treated patients had lost 50% more bone. Bone mineral content decreased only in methylprednisone-treated patients (P〈0.01). Our data suggest that substituting deflazacort for maintenance methylprednisone might prevent height loss, excessive bone loss, and fat accumulation; and leads to an improvement in the lipoproteins of these children.Type of Medium: Electronic ResourceURL: -
20Cortizo, A. M. ; Lee, P. D. K. ; Cédola, N. V. ; Jasper, H. ; Gagliardino, J. J.
Springer
Published 1998Staff ViewISSN: 1432-5233Keywords: Key words Non-enzymatic glycosylation ; Insulin-like growth factor ; Binding proteins ; Chronic complications ; Diabetes mellitusSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract The possible occurrence of increased non-enzymatic glycosylation of serum insulin-like growth factor binding protein-3 (IGFBP-3) in vivo and the changes that would simultaneously occur in serum levels of IGFBP-3 and insulin-like growth factor-1 (IGF-I) were investigated. We measured levels of IGF-I and IGFBP-3 and the degree of glycation of total serum protein and IGFBP-3, in serum samples obtained from patients with poorly controlled non-insulin-dependent diabetes (type 2) and from age-matched non-diabetic controls. Type 2 diabetic patients had significantly higher glycated serum protein (GlyP) levels. GlyP significantly correlated with age in the control (r = 0.315, P〈0.05) but not in the type 2 diabetes group. Control and diabetic subjects had comparable serum IGF-I levels and in both groups IGF-I levels tended to decrease with age (r = –0.567, P〈0.001 and r = –0.465, P〈0.05 for control and type 2 diabetic subjects, respectively). In the type 2 diabetes group, IGF-I levels showed a negative correlation with serum GlyP values (r = –0.476, P〈0.05). Type 2 diabetic and control patients had comparable serum IGFBP-3 levels, which were significantly higher in diabetic patients in the older age subgroups. A negative correlation was found between IGFBP-3 levels and age in the control (r = –0.705, P〈0.001) and in the type 2 diabetes groups (r = –0.463, P〈0.05). A significant negative correlation was found between IGFBP-3 levels and GlyP in control (r = –0.449, P〈0.002) but not in type 2 diabetic subjects. The mean glycated IGFBP-3 (GlyIGFBP-3) levels were higher in the oldest type 2 diabetic patients. In these patients, GlyIGFBP-3 was negatively associated with IGF-I levels (r = –0.447, P〈0.05). The IGF-I/IGFBP-3 molar ratio was significantly reduced in the 46–60-year-old type 2 diabetic group, whereas the IGF-I/IGFBP-3 ratio was positively and significantly correlated with GlyP levels only in the control group (r = 0.489, P〈0.01). Our results show that: a) increased non-enzymatic glycosylation of IGFBP-3 occurs in vivo; and b) this effect is accompanied by an increase in IGFBP-3 levels. These results suggest that the IGF-I/IGFBP-3 system is another target for the metabolic derangements of type 2 diabetes. Its alterations might play a role in diabetic complications.Type of Medium: Electronic ResourceURL: